CJC-1295 no DAC
Anti-Aging, Performance
In short
- A modified fragment of growth hormone-releasing hormone, functionally equivalent to what is also sold as MOD-GRF (1-29).
- The "no DAC" form lacks the drug affinity complex, so its half-life is roughly 30 minutes rather than the several days of the DAC version — a very large practical difference.
- Acts on the GHRH receptor, a different receptor from ipamorelin and the GHRPs, which is the basis for combining them.
- Not approved anywhere. Prohibited at all times in sport.
- Naming in the research market is inconsistent; verify which form you actually have.
Structure
A 29-amino-acid modified GHRH analogue. PubChem has no single entry under this research-market name, and peptides of this length are represented by sequence rather than a small-molecule structure diagram.
How it works
This is GHRH(1-29) — the shortest fragment retaining full GHRH activity — with four amino acid substitutions that resist enzymatic degradation. It binds the GHRH receptor on the anterior pituitary and stimulates GH synthesis and release.
Without the DAC modification it does not bind albumin, so it clears quickly and produces a sharp pulse rather than a sustained elevation. Proponents argue the pulse is more physiological than the continuous elevation the DAC form produces.
What the research shows
GHRH analogues reliably raise GH and IGF-1 in humans; this is well established for the class, and tesamorelin (an approved GHRH analogue) demonstrates it in registrational trials.
For this specific research-market compound, controlled human outcome data does not exist. Body-composition and recovery claims are anecdotal.
Dosing in the literature
Figures below are quoted from published studies, with the species or population they were measured in. They are records of what was studied, not recommendations.
| Studied in | Amount | Route | Source |
|---|---|---|---|
| Human — GHRH(1-29) analogues, GH stimulation studies | Microgram-per-kilogram intravenous doses produce dose-dependent GH release | intravenous | PubMed |
Commonly reported ranges
These are amounts people report using. They are not from any study, have not been evaluated for safety, and are reproduced here only because they circulate widely and are better seen alongside the evidence than instead of it.
| Reported by | Amount | Route |
|---|---|---|
| Commonly reported, often alongside a GHRP | 100 µg, one to three times daily | subcutaneous |
No published human pharmacokinetic study establishes a dose, interval, or duration for this compound. Community figures below have no trial behind them and are reports of practice, not evidence. The 100 µg figure circulating widely is a community convention, not a studied dose.
Handling and storage
Lyophilised powder requiring reconstitution and refrigeration after mixing. Subcutaneous injection.
The short half-life is the operative fact: timing matters far more than for the DAC form, and doses are typically described away from food and near sleep to coincide with natural GH pulses.
Side effects
Reported effects are injection-site reactions, flushing, head-rush shortly after injection, and water retention. GHRH-analogue class effects include joint discomfort and reduced insulin sensitivity.
No long-term human safety data exists for this compound as sold.
Combinations
The canonical pairing is with ipamorelin or another GHRP. GHRH and GHS act on separate receptors and their combination produces a larger GH pulse than either alone — this synergy is documented for the drug classes in endocrinology literature, though not for these specific research-market products.
Research status
The GHRH(1-29) literature is solid at the class level and is the basis for tesamorelin's approval. The specific modified analogue sold as CJC-1295 without DAC has no completed clinical trial of its own.
Legal status
Not approved in any jurisdiction. Sold for research use only. Related GHRH analogues appear on the FDA list of substances presenting significant risks for compounding.
WADA status
PROHIBITED AT ALL TIMES under WADA class S2 — growth hormone secretagogues, their releasing factors and mimetics are explicitly named. Any tested athlete should treat this as an anti-doping violation.
Conclusion
A well-understood mechanism attached to a poorly-documented product. The GHRH receptor pathway is real and the approved analogue tesamorelin proves the class works; that says nothing about the purity, identity, or dose of a vial bought from a research-chemical vendor.
If you use it, know whether you have the DAC or non-DAC form — the pharmacokinetics differ by two orders of magnitude.
Sources
Track your own CJC-1295 no DAC protocol
Peppers logs your doses, models your levels from this half-life, tracks your vials and tells you when you will run out. Free on iPhone.
Reference and educational information only. Not medical advice. Nothing here diagnoses, treats, or prescribes, and nothing here is a recommendation to use any compound. The compounds described are research chemicals and are not approved for human consumption. Legal and anti-doping status change — the review date above is when these claims were last checked. Talk to a qualified clinician about anything you intend to take.